Clinical Trial Update: MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MEDI-573 in combination with standard of care for unresectable or metastatic hepatocellular carcinoma has completed and results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• MEDI-573

Snippet

Sponsor: MedImmune LLC | Conditions: Unresectable or Metastatic Hepatocellular Carcinoma (HCC) | Phase 1 | Status: COMPLETED | Results posted: 2019-02-19